A Taste Assessment of Iberdomide and Mezigdomide in Healthy Participants

Bristol-Myers Squibb (BMS)

Status: Completed

Conditions: Healthy Participants

Study type: Observational

Funder types: Industry

Identifiers

NCT05539976

IM048-015

Details and patient eligibility

About

The purpose of this study is to develop taste profiles of iberdomide and mezigdomide drug substances and oral formulation prototypes in order to develop a pediatric oral form of iberdomide and mezigdomide.

Enrollment: 10 patients

Sex: All

Ages: 25 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participant is qualified based on training and experience.
• Participants must be trained to detect, identify, recognize, and accurately describe different taste elements and flavor combinations. Training is initially accomplished by tasting model compounds and learning to recognize and describe these accurately. These abilities are then honed and refined through additional experience in performing taste profiling.
• Participant is qualified based on training and experience.
• Senopsys LLC will provide all participants.
• Participants must be trained to detect, identify, recognize, and accurately describe different taste elements and flavor combinations. Training is initially accomplished by tasting model compounds and learning to recognize and describe these accurately. These abilities are then honed and refined through additional experience in performing taste profiling.

Exclusion criteria

• Participant has any history of any illness, medical condition, laboratory abnormality, or psychiatric illness that, in the opinion of the investigator, might confound the results of the study or places the participant at unacceptable risk if he or she were to participate in the study.
• Participant has a known hypersensitivity to mezigdomide, iberdomide, thalidomide, lenalidomide, or pomalidomide.
• Participant is a female that is pregnant, breastfeeding, or is a women of childbearing potential (WOCBP).

Trial design

10 participants in 1 patient group

Healthy participants who perform taste evaluations

Description:

A maximum of 10 healthy adult participants will complete a maximum of 30 taste assessment days, to evaluate the taste characteristics of iberdomide or mezigdomide on each taste assessment day.